The amount of capital invested alongside corporate venture capital (CVC) into UK companies increased six-fold between 2010 and 2015, marking a fundamental shift in how start-up British biotech is funded, new research has shown.
The amount of capital invested alongside CVC into UK companies increased six-fold between 2010 and 2015 – image courtesy of Depositphotos. Corporate venture capital, where pharma companies invest their own funds in emerging start-ups, is now established as a key source of capital for biotech innovation in the UK, according to…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
